Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota.
Animals
Bacteria
/ metabolism
ErbB Receptors
/ metabolism
Gastrointestinal Microbiome
Heparin-binding EGF-like Growth Factor
/ metabolism
Irritable Bowel Syndrome
Mice
Probiotics
/ pharmacology
Saccharomyces boulardii
/ metabolism
Serotonin
/ metabolism
Serotonin Plasma Membrane Transport Proteins
/ genetics
5-hydroxytryptamine
Gut microbiota
Gut motility
Saccharomyces boulardii
Serotonin transporter
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
15
03
2022
revised:
30
05
2022
accepted:
05
06
2022
pubmed:
12
6
2022
medline:
22
6
2022
entrez:
11
6
2022
Statut:
ppublish
Résumé
Saccharomyces boulardii (Sb) is a widely used fungal probiotic in treating various digestive diseases, including irritable bowel syndrome (IBS). However, the specific mechanisms of Sb relieving IBS remain unclear. The abnormal serotonin transporter (SERT) / 5-hydroxytryptamine (5-HT) system could cause disordered gastrointestinal sensation and motility, which closely related to IBS pathogenesis. The aim of this study was to explore the effects and mechanisms of Sb on regulating gut motility. Sb supernatant (SbS) was administered to intestinal epithelial cells and mice. SbS upregulated SERT expression via enhancing heparin-binding epidermal growth factor (HB-EGF) release to activate epidermal growth factor receptor (EGFR). EGFR kinase inhibitor treatment or HB-EGF siRNA transfection in cells blocked SbS upregulating SERT. Consistently, SbS-treated mice presented inhibited gut motility, and EGFR activation and SERT upregulation were found. Moreover, 16 S rDNA sequence presented an evident decrease in Firmicutes / Bacteroidetes ratio in SbS group. In genus level, SbS reduced Escherichia_Shigella, Alistipes, Clostridium XlVa, and Saccharibacteria_genera_incertae_sedis, meanwhile, increased Parasutterella. The abundance of Saccharibacteria_genera_incertae_sedis positively correlated with defecation parameters and intestinal 5-HT content. Fecal microbiota transplantation showed that SbS could modulate gut microbiota to influence gut motility. Interestingly, elimination of gut microbiota with antibiotic cocktail did not entirely block SbS regulating gut motility. Furthermore, SbS administration to IBS-D mice significantly upregulated SERT and inhibited gut motility. In conclusion, SbS could upregulate SERT by EGFR activation, and modulate gut microbiota to inhibit gut motility. This finding would provide more evidence for the application of this yeast probiotic in IBS and other diarrheal disorders.
Identifiants
pubmed: 35690329
pii: S1043-6618(22)00236-5
doi: 10.1016/j.phrs.2022.106291
pii:
doi:
Substances chimiques
Heparin-binding EGF-like Growth Factor
0
Serotonin Plasma Membrane Transport Proteins
0
Serotonin
333DO1RDJY
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106291Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.